Striant Germany Launch

Ardana PLC
05 October 2005



      ARDANA ANNOUNCES GERMAN LAUNCH OF STRIANT(TM) SR THROUGH CYTOCHEMIA AG


Edinburgh, UK, 5th October 2005;  Ardana plc (LSE:ARA), the emerging
pharmaceutical company focused on improving human reproductive health, announces
that its partner, Cytochemia AG, has commenced marketing of Striant(TM) SR,
Ardana's testosterone replacement therapy for male hypogonadism, in Germany.

The German launch of Striant(TM) SR was announced at the 57th Congress of the
German Society of Urology meeting in Dusseldorf, which was attended by
approximately 3,000 urologists. Striant(TM) SR is now available on prescription
in Germany which, with an estimated size of €15.2 million per annum*, is the
largest market for testosterone replacement therapies in Europe.  Cytochemia AG
will target all 3,500 urologists plus andrologists in the country.

This follows the announcement of Ardana's German sales and marketing agreement
with Cytochemia on Striant(TM) SR on 16th June 2005. Financial terms of the
German distribution partnership were not disclosed but Ardana received an
upfront payment and will have ongoing revenues for the supply of Striant(TM) SR
to Cytochemia.

In addition, Ardana also announces today that Mode Medical has been appointed
sales and marketing agent, responsible for promoting Striant(TM) SR to
endocrinology consultants in Ireland. With an estimated size of €0.25 million
and a growth rate of 42% per annum, the Irish market is small but fast growing.

Striant(TM) SR is a mucoadhesive buccal (gum surface) tablet containing 30mg of
testosterone and is indicated as a replacement therapy for male hypogonadism
when deficiency of testosterone has been confirmed. Striant(TM) SR is the
first-to-market buccal adhesive tablet and is marketed by Ardana's own sales
force in the UK, to urologists and endocrinologists. Other therapies for male
hypogonadism include injectable formulations of testosterone, oral preparations,
transdermal patches, topical gels and sub-cutaneous implants.

Dr. Maureen Lindsay, Chief Executive of Ardana, said:

'Today's announcement demonstrates Ardana's commitment to expand in key European
markets and underlines its determination to introduce novel therapies for
indications where there are unmet patient needs. '


*Source: MAT June 2005, IMS data


For more information contact:

 Ardana                                  Financial Dynamics
 Maureen Lindsay                         (corporate/financial media relations)
 Tel: + 44 (0) 131 226 8550              Julia Phillips/Davina Langdale
                                         Tel: [phone]

                                         NB Public Relations
                                         (trade/technical media relations)
                                         Nicki Brimicombe
                                         Tel: + 44 (0)1883 732353



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.

Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.

Ardana's four lead products are summarised below:

  • Striant(TM) SR, a testosterone replacement therapy that has already been
    launched by Ardana through its own sales force in the UK as a treatment for
    men with hypogonadism and for which Ardana has marketing rights in Europe;
  • Teverelix LA, in development for three initial indications (prostate
    cancer, benign prostatic hyperplasia and endometriosis);
  • Testo Bi-gel, a trans dermal testosterone delivery system in development
    for the treatment of male hypogonadism, shortly to enter Phase II trials;
  • Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.


In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana completed its IPO on the London Stock Exchange in March 2005 raising £21
million.

For further information please see www.ardana.co.uk


Cytochemia

Cytochemia is an independent pharmaceutical company based in Germany
specializing in immuno-therapeutics from either their own product development or
exclusive licence agreements. The target group for Cytochemia's therapeutics
consists of gynaecologists, oncologists and urologists. The company is primarily
active in the German market but in 2000 the company founded another branch of
the business in Switzerland.

Cytochemia has considerable experience in Germany selling to the same
specialists as Ardana through their targeted sales force which has a strong
track record in the education of physicians on product usage. Cytochemia has a
strong complementary portfolio to Ardana and its product ImmuCyst, which has
been on the market for 13 years, is an established agent for the treatment and
prevention of superficial bladder cancer. Striant(TM) SR presents an excellent
strategic fit with Cytochemia's product portfolio and will be an important
addition.




                      This information is provided by RNS
            The company news service from the London Stock Exchange